SB-271046

SB-271046

Systematic (IUPAC) name
5-chloro-N-(4-methoxy-3-piperazin-1-ylphenyl)-3-methyl-1-benzothiophene-2-sulfonamide
Identifiers
PubChem	CID: 5312149
IUPHAR/BPS	276
ChemSpider	4471579 N
ChEMBL	CHEMBL431298 N
Chemical data
Formula	C20H22ClN3O3S2
Molecular mass	451.989 g/mol
SMILES C4CNCCN4c3cc(ccc3OC)NS(=O)(=O)c1sc2ccc(Cl)cc2c1C
InChI InChI=1S/C20H22ClN3O3S2/c1-13-16-11-14(21)3-6-19(16)28-20(13)29(25,26)23-15-4-5-18(27-2)17(12-15)24-9-7-22-8-10-24/h3-6,11-12,22-23H,7-10H2,1-2H3 N Key:LOCQRDBFWSXQQI-UHFFFAOYSA-N N
NY (what is this?)  (verify)

SB-271046 is a drug which is used in scientific research. It was one of the first selective 5-HT₆ receptor antagonists to be discovered, and was found through high-throughput screening of the SmithKline Beecham Compound Bank using cloned 5-HT₆ receptors as a target, with an initial lead compound being developed into SB-271046 through a structure-activity relationship (SAR) study. SB-271046 was found to be potent and selective in vitro and had good oral bioavailability in vivo, but had poor penetration across the blood–brain barrier, so further SAR work was then conducted, which led to improved 5-HT₆ antagonists such as SB-357,134 and SB-399,885.

SB-271046 was found to increase levels of the excitatory amino acid neurotransmitters glutamate and aspartate, as well as dopamine and noradrenaline in the frontal cortex and hippocampus of rats, and 5-HT₆ antagonists have been shown to produce nootropic effects in a variety of animal studies. Suggested applications of these drugs include treatment of schizophrenia and other psychiatric disorders.